Egg Medical Rampart – Press Release July 29, 2025

Aug 1, 2025 | Blog

U.S. Patent and Trademark Office Issues Final Rejection of All Claims in Rampart IC’s Radiation Shield Patent Following a Reexamination Challenge by Egg Medical

ST. PAUL, Minnesota, United States – In a significant development in an ongoing legal dispute, the U.S. Patent and Trademark Office (USPTO) has issued a final rejection of all claims in U.S. Patent No. 11,660,056 held by Rampart IC, LLC related to a radiation shielding device. The decision follows a request for reexamination by Egg Medical, Inc., which argued that Rampart’s ’056 patent covered technology that had already been invented—some examples dating as far back as the 1960s.

Egg Medical’s reexamination request arose out of a lawsuit that Rampart filed in federal court in 2024, in which Rampart alleged that Egg Medical had infringed on its ’056 patent. However, after the USPTO twice rejected all claims in the ’056 patent, the federal judge overseeing the case stayed the proceedings pending the outcome of the reexamination. In July 2025, the USPTO issued a final rejection of all claims, citing multiple prior inventions—two of which were developed by Egg Medical.

“

The remarkable part of this lawsuit is that Egg Medical never sold any product that fell within the scope of Rampart’s now-rejected patent claims. Egg Medical respects prior intellectual property. The USPTO rejecting the claims in Rampart’s asserted ’056 patent validates what we have been saying all along.”
– Robert F. Wilson, MD, CEO of Egg Medical

“

The lawsuit was harmful to our company, as Rampart’s sales team at times suggested to customers that we were infringing on their ’056 patent—an assertion that was never true. We’re pleased that the USPTO has thoroughly and repeatedly rejected all of Rampart’s claims in that patent, and we’re glad our customers now have clarity.”

– Gavin Philipps, Chief Commercial Officer
at Egg Medical

Rampart IC may still respond to the USPTO’s final rejection or appeal to the Patent Trial and Appeal Board. After three rounds and a sweeping final rejection, however, Rampart’s options are dwindling.